Recurrent Clostridium Difficile Infection
13
1
1
7
Key Insights
Highlights
Success Rate
78% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
15.4%
2 terminated out of 13 trials
77.8%
-8.7% vs benchmark
31%
4 trials in Phase 3/4
86%
6 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (13)
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
Fecal Microbiota Transplantation (FMT): PRIM-DJ2727
Dietary Optimization of Microbiome Recovery Following Fecal Microbiota Transplantation
Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection
Primary or Recurrent Clostridioides Difficile Infection Treatment With Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin
Lyophilized Fecal Microbiota Transplantation for Recurrent Clostridioides Difficile Infection
Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection
Fecal Filtrate as a Treatment Option of Multiple Recurrent Clostridioides Difficile Infection
Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection
Lyophilized Fecal Transplant vs Lyophilized Fecal Filtrate in Recurrent C Diff Infection
Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea
BIO-K+ CL1285 for Prevention of Recurrent Clostridium Difficile Infection
Oral Vancomycin Followed by Fecal Transplant Versus Tapering Oral Vancomycin